A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
Q3 2025 Management View CEO Jerrell Shelton highlighted double-digit growth in both Life Sciences Services and Life Sciences Product segments, noting "revenue from our support of commercial cell and ...
TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...
Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, today announced the closing of a $4.6 million seed financing led by ...
The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasd ...
Nov. 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using ... for the ...
Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback